Detailed information for compound 1677950
Basic information
Technical information
- Name: Unnamed compound
- MW: 432.432 | Formula: C22H20N6O4
-
H donors: 1
H acceptors: 6
LogP: 1.76
Rotable bonds: 7
Rule of 5 violations (Lipinski): 1 - SMILES: Cc1cnc(cn1)NC(=O)c1cc(Oc2cnc(nc2)C(=O)N(C)C)c2c(c1)oc(c2)C
- InChi: 1S/C22H20N6O4/c1-12-8-24-19(11-23-12)27-21(29)14-6-17-16(5-13(2)31-17)18(7-14)32-15-9-25-20(26-10-15)22(30)28(3)4/h5-11H,1-4H3,(H,24,27,29)
- InChiKey: MASKQITXHVYVFL-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Rattus norvegicus | Hexokinase type IV | Starlite/ChEMBL | References |
| Homo sapiens | glucokinase (hexokinase 4) | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Candida albicans | N-acetylglucosamine kinase | Hexokinase type IV | 465 aa | 393 aa | 22.6 % |
| Onchocerca volvulus | Hexokinase type IV | 465 aa | 456 aa | 45.0 % | |
| Brugia malayi | Hexokinase family protein | Hexokinase type IV | 465 aa | 472 aa | 29.2 % |
| Onchocerca volvulus | Putative electron transfer flavoprotein subunit alpha, mitochondrial | Hexokinase type IV | 465 aa | 460 aa | 45.0 % |
| Onchocerca volvulus | Hexokinase type IV | 465 aa | 453 aa | 40.4 % | |
| Candida albicans | N-acetylglucosamine kinase | Hexokinase type IV | 465 aa | 393 aa | 22.6 % |
| Brugia malayi | Hexokinase family protein | glucokinase (hexokinase 4) | 465 aa | 470 aa | 30.0 % |
| Onchocerca volvulus | Hexokinase type IV | 465 aa | 458 aa | 42.4 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Schistosoma mansoni | sex comb on midleg homolog | 0.5073 | 0.2889 | 0.2889 |
| Trypanosoma cruzi | Kinesin-13 5, putative | 0.0481 | 0 | 0.5 |
| Plasmodium falciparum | JmjC domain-containing protein, putative | 0.0555 | 0.0046 | 0.5 |
| Echinococcus granulosus | tumor suppressor p53 binding protein 1 | 0.6247 | 0.3628 | 0.6089 |
| Echinococcus multilocularis | histone acetyltransferase MYST2 | 0.1829 | 0.0848 | 0.1424 |
| Brugia malayi | C2-HC type zinc finger protein C.e-MyT1 | 0.1829 | 0.0848 | 0.1635 |
| Schistosoma mansoni | chromodomain helicase DNA binding protein | 0.0516 | 0.0022 | 0.0022 |
| Echinococcus multilocularis | chromobox protein 2 | 0.3762 | 0.2065 | 0.3464 |
| Echinococcus multilocularis | histone acetyltransferase myst3 | 0.0778 | 0.0186 | 0.0313 |
| Echinococcus granulosus | lysine specific demethylase 5A | 0.1776 | 0.0815 | 0.1367 |
| Trichomonas vaginalis | cgi-62, putative | 0.0481 | 0 | 0.5 |
| Echinococcus multilocularis | chromodomain helicase DNA binding protein 4 | 0.0516 | 0.0022 | 0.0036 |
| Trypanosoma brucei | SAM domain (Sterile alpha motif), putative | 0.0481 | 0 | 0.5 |
| Schistosoma mansoni | myelin transcription factor 1 myt1 | 0.1829 | 0.0848 | 0.0848 |
| Onchocerca volvulus | 0.576 | 0.3322 | 0.6402 | |
| Loa Loa (eye worm) | hypothetical protein | 0.1829 | 0.0848 | 0.1635 |
| Brugia malayi | mbt repeat family protein | 0.5279 | 0.3019 | 0.5818 |
| Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.0485 | 0.0002 | 0.0004 |
| Echinococcus granulosus | polycomb protein SCMH1 | 0.5073 | 0.2889 | 0.4848 |
| Echinococcus granulosus | histone acetyltransferase MYST2 | 0.1829 | 0.0848 | 0.1424 |
| Brugia malayi | jmjC domain containing protein | 0.0485 | 0.0002 | 0.0005 |
| Echinococcus granulosus | SAM and MBT domain containing protein | 0.7347 | 0.432 | 0.725 |
| Echinococcus multilocularis | Jumonji, AT rich interactive domain 1B | 0.2178 | 0.1068 | 0.1792 |
| Schistosoma mansoni | sex comb on midleg homolog | 0.5073 | 0.2889 | 0.2889 |
| Trichomonas vaginalis | c2h2 zinc finger protein, putative | 0.0481 | 0 | 0.5 |
| Echinococcus granulosus | histone acetyltransferase myst3 | 0.0778 | 0.0186 | 0.0313 |
| Echinococcus granulosus | suppression of tumorigenicity 18 protein | 0.1829 | 0.0848 | 0.1424 |
| Trypanosoma cruzi | Kinesin-13 5, putative | 0.0481 | 0 | 0.5 |
| Echinococcus multilocularis | tumor suppressor p53 binding protein 1 | 0.6247 | 0.3628 | 0.6089 |
| Echinococcus multilocularis | polycomb protein SCMH1 | 0.5073 | 0.2889 | 0.4848 |
| Loa Loa (eye worm) | mbt repeat family protein | 0.5279 | 0.3019 | 0.5818 |
| Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.0485 | 0.0002 | 0.0004 |
| Echinococcus multilocularis | endonuclease exonuclease phosphatase | 0.9951 | 0.5959 | 1 |
| Echinococcus multilocularis | SAM and MBT domain containing protein | 0.7347 | 0.432 | 0.725 |
| Trypanosoma cruzi | hypothetical protein | 0.0481 | 0 | 0.5 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0481 | 0 | 0.5 |
| Onchocerca volvulus | Polycomb protein Sfmbt homolog | 0.8727 | 0.5189 | 1 |
| Schistosoma mansoni | scm-relatedprotein containing 4 mbt domains (sfmbt) | 0.7347 | 0.432 | 0.432 |
| Schistosoma mansoni | jumonji/arid domain-containing protein | 0.1776 | 0.0815 | 0.0815 |
| Echinococcus granulosus | Jumonji AT rich interactive domain 1B | 0.2178 | 0.1068 | 0.1792 |
| Schistosoma mansoni | jumonji domain containing protein | 0.0485 | 0.0002 | 0.0002 |
| Schistosoma mansoni | phd finger protein | 0.0778 | 0.0186 | 0.0186 |
| Loa Loa (eye worm) | hypothetical protein | 0.8727 | 0.5189 | 1 |
| Schistosoma mansoni | chromobox protein | 0.3762 | 0.2065 | 0.2065 |
| Brugia malayi | jmjC domain containing protein | 0.2615 | 0.1343 | 0.2588 |
| Toxoplasma gondii | histone lysine demethylase JMJC1/KDM5D/JARID1D | 0.0618 | 0.0086 | 0.3694 |
| Plasmodium vivax | JmjC domain containing protein | 0.0555 | 0.0046 | 1 |
| Loa Loa (eye worm) | MBCTL1 | 0.1829 | 0.0848 | 0.1635 |
| Giardia lamblia | Giardia trophozoite antigen GTA-1 | 0.0481 | 0 | 0.5 |
| Giardia lamblia | Kinesin-13 | 0.0481 | 0 | 0.5 |
| Toxoplasma gondii | PLU-1 family protein | 0.0839 | 0.0225 | 1 |
| Echinococcus granulosus | endonuclease exonuclease phosphatase | 0.9951 | 0.5959 | 1 |
| Echinococcus multilocularis | suppression of tumorigenicity 18 protein | 0.1829 | 0.0848 | 0.1424 |
| Loa Loa (eye worm) | jmjC domain-containing protein | 0.2615 | 0.1343 | 0.2588 |
| Schistosoma mansoni | hypothetical protein | 0.6247 | 0.3628 | 0.3628 |
| Echinococcus granulosus | chromodomain helicase DNA binding protein 4 | 0.0516 | 0.0022 | 0.0036 |
| Echinococcus multilocularis | lysine specific demethylase 5A | 0.148 | 0.0628 | 0.1055 |
| Echinococcus granulosus | chromobox protein 2 | 0.3762 | 0.2065 | 0.3464 |
| Trypanosoma brucei | Present in the outer mitochondrial membrane proteome 24 | 0.0481 | 0 | 0.5 |
| Brugia malayi | CHD4 protein | 0.0516 | 0.0022 | 0.0042 |
| Brugia malayi | mbt repeat family protein | 0.8727 | 0.5189 | 1 |
| Schistosoma mansoni | jumonji/arid domain-containing protein | 0.1776 | 0.0815 | 0.0815 |
| Loa Loa (eye worm) | CHromoDomain protein family member | 0.0516 | 0.0022 | 0.0042 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (binding) | Induction of glucokinase translocation from nucleus to cytoplasm in cryopreserved rat hepatocytes after 1 hr by Hoechst staining-based fluorescence microscopic analysis | ChEMBL. | 22196621 | |
| Activity (binding) | Activation of glucokinase in Sprague-Dawley rat islets assessed as enhancement of glucose-stimulated insulin secretion after 60 mins by enzyme immunoassay | ChEMBL. | 22196621 | |
| Activity (binding) | Induction of glucokinase translocation from nucleus to cytoplasm in rat hepatocytes in presence of 8.9 mM glucose | ChEMBL. | No reference | |
| CL (ADMET) | < 8 ml/min.kg | Intrinsic clearance in human liver microsomes | ChEMBL. | No reference |
| EC50 (binding) | = 174 nM | Activation of recombinant human glucokinase assessed as formation of glucose-6-phosphate by G6PDH/NADP coupled assay | ChEMBL. | No reference |
| EC50 (binding) | = 188 nM | Activation of human recombinant glucokinase using 6.5 mM glucose by spectrophotometric analysis | ChEMBL. | 22196621 |
| EC50 (binding) | = 188 nM | Activation of recombinant human glucokinase assessed as formation of glucose-6-phosphate by G6PDH/NADP coupled assay | LITERATURE. | No reference |
| EC50 (binding) | = 407 nM | Activation of rat glucokinase | ChEMBL. | No reference |
| EC50 (binding) | = 0.19 uM | Activation of human recombinant glucokinase by matrix assay in presence of glucose | ChEMBL. | 23831135 |
| EC50 (binding) | = 0.6 uM | Induction of glucokinase translocation from nucleus to cytoplasm in rat hepatocytes in presence of 15 mM glucose | ChEMBL. | No reference |
| EC50 (binding) | = 0.9 uM | Induction of glucokinase translocation from nucleus to cytoplasm in cryopreserved rat hepatocytes after 1 hr by Hoechst staining-based fluorescence microscopic analysis | ChEMBL. | 22196621 |
| EC50 (binding) | = 0.9 uM | Induction of glucokinase translocation from nucleus to cytoplasm in rat hepatocytes in presence of 8.9 mM glucose | ChEMBL. | No reference |
| EC50 (binding) | = 2.3 uM | Induction of glucokinase translocation from nucleus to cytoplasm in rat hepatocytes in presence of 5.5 mM glucose | ChEMBL. | No reference |
| EC50 (binding) | = 3.8 uM | Induction of glucokinase translocation from nucleus to cytoplasm in rat hepatocytes in presence of 2.5 mM glucose | ChEMBL. | No reference |
| FC (ADMET) | > 2 | Drug uptake by human hepatic OATP1B3 transporter expressed in HEK293 cells relative to control | ChEMBL. | 22196621 |
| FC (ADMET) | > 2 | Drug uptake by human hepatic OATP1B1 transporter expressed in HEK293 cells relative to control | ChEMBL. | 22196621 |
| Inhibition (binding) | = 0 % | Inhibition of dofetilide binding to human ERG at 10 uM relative to control | ChEMBL. | No reference |
| K (binding) | = 72.7 10'-3/s | Binding affinity to biotinylated human recombinant glucokinase expressed in Escherichia coli assessed as off rate constant for activator-enzyme binding kinetics by SPR method | ChEMBL. | No reference |
| K (binding) | = 107 10'-3/s | Binding affinity to biotinylated rat recombinant glucokinase expressed in Escherichia coli assessed as off rate constant for activator-enzyme binding kinetics by SPR method | ChEMBL. | No reference |
| K (binding) | = 3.79 10'5/M/s | Binding affinity to biotinylated human recombinant glucokinase expressed in Escherichia coli assessed as on rate constant for activator-enzyme binding kinetics by SPR method | ChEMBL. | No reference |
| Kd (binding) | = 189.2 nM | Binding affinity to biotinylated human recombinant glucokinase expressed in Escherichia coli assessed as dissociation rate constant by SPR method | ChEMBL. | No reference |
| Ratio (binding) | = 0.1 | Activation of human recombinant glucokinase assessed as ratio of the glucokinase Km at maximum compound concentration to the enzyme Km in the absence of compound | ChEMBL. | 23831135 |
| Ratio (binding) | = 0.87 | Activation of human recombinant glucokinase assessed as ratio of the enzyme velocity at maximum compound concentration to the enzyme Km in the absence of compound | ChEMBL. | 23831135 |
| T1/2 (binding) | = 9.7 s | Binding affinity to biotinylated human recombinant glucokinase expressed in Escherichia coli assessed as dissociation half life by SPR method | ChEMBL. | No reference |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL2165615
Bibliographic References
2 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.